hDesmin-SaCas9HF AAV (Serotype 9)

hDesmin-SaCas9HF AAV (serotype 9) is specifically designed to express high-fidelity Staphylococcus aureus Cas9 (SaCas9) under the control of the human Desmin promoter. AAV is renowned in the field of gene therapy for its high efficiency, safety, and long-term expression profile, making it an ideal vector for delivering genetic material into cells. Serotype 9 is particularly favored for its broad tropism and ability to transduce a variety of cell types (including muscle cells, liver cells, and central nervous system cells) without integrating into the host genome, thereby minimizing the risk of insertional mutagenesis.

Staphylococcus aureus Cas9 (SaCas9) is a variant of the popular CRISPR-Cas9 system derived from Streptococcus pyogenes (SpCas9). SaCas9 is characterized by its small size, which facilitates packaging into AAV vectors with limited capacity. In addition, the high-fidelity (HF) version of SaCas9 significantly reduces off-target effects, thereby improving the precision of gene editing, thereby enhancing the safety and specificity required for therapeutic applications. The hDesmin promoter is a muscle-specific promoter that primarily drives SaCas9 expression in muscle tissue. This specificity is particularly beneficial for targeted therapeutic strategies against muscle-related diseases such as muscular dystrophy and cardiomyopathy. By utilizing the hDesmin promoter, researchers can achieve localized editing of muscle cells, thereby maximizing therapeutic efficacy while minimizing potential side effects in non-target tissues.